# PURMX Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/purmx-therapeutics

- Industry: Biotechnology
- Headquarters: Hiroshima-shi, Japan
- Website: www.purmx.com
- Total disclosed funding: $9M
- Latest round: Series A (May 7, 2024)
- Investors on record: 7

## About

Founded in 2021 and based in Hiroshima, Japan, PURMX Therapeutics, Inc. operates as a research and development company that develops nucleic acid drugs containing microRNA as an active ingredient. The company develops treatments for malignant thoracic tumors. In May 2022, PURMX Therapeutics, Inc. raised JPY 850 million in Series A funding from new investors Hiroshima Venture Capital, Mitsubishi UFJ Capital, Osaka University Venture Capital, QB Capital, and University of Tokyo Edge Capital Partners.

The company operates as a drug developer, which focuses on replacing lacking small RNAs (microRNA) in cells. The company now has one pipeline undergoing, MIRX002, a nucleic acid medicine for malignant pleural mesothelioma.

## Funding rounds

- Series A, May 7, 2024, $2M — Keio Innovation Initiative
- Series A, Nov 30, 2023, $0.3M — Yokohama Capital
- Series A, May 31, 2022, $6.7M — University of Tokyo Edge Capital Partners, Mitsubishi UFJ Capital, Osaka University Venture Capital, Hiroshima Venture Capital, QB Capital

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A
- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series A
- Hiroshima Venture Capital (https://capitalatlas.ai/funds/hiroshima-venture-capital) — Series A
- QB Capital (https://capitalatlas.ai/funds/qb-capital) — Series A
- Yokohama Capital (https://capitalatlas.ai/funds/yokohama-capital) — Series A
- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Series A